Key result
Dabigatran was associated with similar rates of ischemic stroke compared to warfarin in Asian patients with atrial fibrillation (0% vs 0.8%; HR 0.13, P=0.3).
Why the study?
Does dabigatran reduce ischemic stroke, hemorrhagic stroke, and major bleeding compared to warfarin in Asian patients with atrial fibrillation?
Population
1000 Asian patients with atrial fibrillation (n=1000)
Comparison
Dabigatran vs Warfarin
Design
Cohort
Follow-up
Average 315 ± 280 days in the dabigatran group and 355 ±…
Authors
Loading...
Supports similar ischemic stroke rates with dabigatran in Asian AF; leaves open need for RCTs to guide NOAC preference.
Cohort (n=1,000)
Does dabigatran reduce ischemic stroke, hemorrhagic stroke, and major bleeding compared to warfarin in Asian patients with atrial fibrillation?
Hazard Ratio: 0.13
Absolute Event Rate: 0% vs 0.8%
p-value: p=.3
Dabigatran demonstrated similar efficacy and safety to warfarin for stroke prevention in an Asian atrial fibrillation cohort, supporting the preference for NOACs given the suboptimal time in therapeutic range observed with warfarin.
Yap et al. (2015) conducted a cohort in Atrial fibrillation (n=1,000). Dabigatran vs. Warfarin was evaluated on Ischemic cerebrovascular accident (CVA) (HR 0.13, p=.3). Dabigatran was associated with similar rates of ischemic stroke compared to warfarin in Asian patients with atrial fibrillation (0% vs 0.8%; HR 0.13, P=0.3).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: